All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Razuprotafib a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase, is being developed as a treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nalbuphine Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Haduvio
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Patient screening has resumed for the Phase 2 trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), a trial that was paused due to IPF patients being an at-risk population for COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Synairgen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2020
Details:
Synairgen’s study will evaluate the ability of SNG001, an inhaled formulation of IFN-beta-1a, to accelerate recovery among hospitalized patients receiving oxygen.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vardenafil Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RT234-PAH
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
RT234-PAH, based on its rapid onset of action, extended duration of action, and minimal safety and tolerability issues when used in addition to PAH maintenance therapies may allow patients to acutely relieve their episodic symptoms of PAH and improve their quality of life.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GB001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The primary endpoint of the trial was not met, though consistent and meaningful numeric reductions in the odds of asthma worsening as compared to placebo were observed across all GB001 groups.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The multi-center Phase 2 trial is a randomized, double-blind, placebo-controlled study to evaluate the effects of three dose levels of oral dexpramipexole for 12 weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DB-001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ExoFlo
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Direct Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 09, 2020
Details:
Under the terms of the agreement, Direct Biologics will leverage Bioclinica’s Interactive Response Technology (IRT) for their EXIT COVID-19 study, a multi-center FDA phase II clinical trial for the use of ExoFlo™ to treat COVID-19 acute respiratory distress syndrome (ARDS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GB001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
Gossamer Bio will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Genistein
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BIO 300
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Humanetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 19, 2020
Details:
Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Etokimab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ANB020
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2020
Details:
AnaptysBio presented full data from its Phase 2a proof-of-concept clinical trial of etokimab in adult patients with severe eosinophilic asthma at the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
